Rivastigmine Mini-Tablet for Alzheimer's Disease

Not yet recruitingOBSERVATIONAL

Enrollment

1,000

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Alzheimer's Disease

Interventions

DRUG

Rivastigmine Mini-Tablet

Treatment group: Rivastigmine Mini-Tablet

DRUG

Donepezil Hydrochloride

Control group: Donepezil Hydrochloride

All Listed Sponsors

lead

Peking University First Hospital

OTHER

NCT06828289 - Rivastigmine Mini-Tablet for Alzheimer's Disease | Biotech Hunter | Biotech Hunter